ASSESSMENT OF HLA-COMPATIBILITY AND REQUIREMENTS FOR HLA-TYPING OF PATIENT AND DONOR IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
https://doi.org/10.35754/0234-5730-2019-64-2-175-187
Abstract
Introduction. Unification of guidelines and standards concerning requirements for HLA typing and assessment of the degree of HLA match between the recipient and the donor for different types of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is of a great importance.
Aim. To present contemporary requirements for the HLA typing of a recipient and a donor for allo-HSCT, to generalize recom mendations for assessing a required match degree of a recipient and a donor and to provide data on additional immunogenetic factors capable of improving the results of allogeneic hematopoietic stem cell transplantation.
General findings. Allo-HSCT appears to be an effective, and, in some cases, non-alternative treatment for many diseases of the blood system. The number of allo-HSCT types is constantly growing globally. Currently, an allogeneic hematopoietic stem cell donor can be selected for almost every recipient having indication for this type of therapy. Such a transplantation can be performed from an HLA-identical sibling, an HLA-match unrelated donor, a partially HLA-match unrelated donor, a relative haploidentical donor or cord blood. HLA match between the recipient and the donor present itself as an important factor affecting the results of allo-HSCT. The choice of a donor should involve a correct assessment the HLA match degree between the recipient and the donor, as well as consideration of additional factors that may affect the results of allo-HSCT.
About the Authors
E. G. Khamaganova
National Research Center for Hematology
Russian Federation
Russian Federation
Ekaterina G. Khamaganova, Head of the Tissue Typing Laboratory
tel.:+7 (495) 612-43-02; 125167, Moscow, Novyy Zykovskiy proezd, 4.
L. A. Kuzmina
National Research Center for Hematology
Russian Federation
Larisa A. Kuzmina, Head of the Department of Intensive High-Dose Chemotherapy and Bone Marrow Transplantation
Russian Federation
Larisa A. Kuzmina, Head of the Department of Intensive High-Dose Chemotherapy and Bone Marrow Transplantation
References
1. Diagnostic algorithms and protocols for the treatment of blood system diseases. Savchenko V.G., ed. Moscow: Praktika; 2018. V. 1. 1008 p. (In Russian).
2. Diagnostic algorithms and protocols for the treatment of blood system diseases. Savchenko V.G., ed. Moscow: Praktika; 2018. V. 2. 1264 p. (In Russian).
3. Passweg J.R., Baldomero H., Bader P., Basak G.W., Bonini C., Duarte R., et al. Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2018; 53(9): 1139–48. DOI: 10.1038/s41409-018-0153
4. Passweg J.R., Baldomero H., Bader P., et al. The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. Bone Marrow Transplant. Bone Marrow Transplant. 2019. DOI: 10.1038/s41409-019-0465-9 [Epub ahead of print]
5. Howard C.A., Fernandez-Vina M.A., Appelbaum F.R., et al. Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Transplant. 2015; 21(1): 4–7. DOI: 10.1016/j.bbmt.2014.09.017
6. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides. 2017. http://www.cibmtr.org
7. EFI Standards for histocompatibility and immunogenetics testing. 2018. https:// www.efi-web.org/news/version-7-of-the-standards-for-histocompatibility-immunogentics-testing.html
8. Tiercy J.M. How To Select The Best Available Related Or Unrelated Donor Of Hematopoietic Stem Cells? Haematologica. 2016; 101: 680–7. DOI: 10.3324/ haematol.2015.141119
9. Zaretskaya Y.M., Khamaganova E.G., Gubarev M.I. Human immunogenetics and immunology. Moscow: Triada-farm; 2002. 138 p (In Russian).
10. Fleischhauer K., Fernandez-Viña M.A., Wang T., et al. Risk associations between HLA-DPB1 T-cell epitope matching and outcome of unrelated hematopoietic cell transplantation are independent of HLA-DPA1. Bone Marrow Transplantation. 2014; 49: 1176–83. DOI: 10.1038/bmt.2014.122
11. European Bioinformatics Institute. IPD-IMGT/HLA Database. https://www. ebi.ac.uk/ipd/imgt/hla/statistics
12. Khamaganova E.G., Kuzminova E.P., Parovichnikova E.N., et al. Probability of the finding the hla-identical related donor for patients with hematological disorders from families with different numbers of children. Genatologiya I Transfusiologiya. 2017; 62(1): 29–32. DOI: http://dx.doi.org/10.18821/0234-5730- 2017-62-1-29-32 (In Russian).
13. Lee S.J., Klein J., Haagenson M., et al. High resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007; 110: 4576–83. DOI: 10.1182/blood-2007-06-097386
14. Woolfrey A., Klein J.P., Haagenson M., et al. HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2011; 17: 885–92. DOI: 10.1016/j.bbmt.2010.09.012
15. Spellman S.R., Eapen M., Logan B.R., et al. A perspective on the selection of unrelated donors and cord blood units for transplantation. Blood. 2012; 120: 259–65. DOI: 10.1182/blood-2012-03-379032
16. Kollman C., Spellman S.R., Zhang M.J., et al. The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. Blood. 2016; 127: 260–7. DOI: 10.1182/blood-2015-08-663823
17. Fürst D., Müller C., Vucinic V., et al. High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis. Blood. 2013; 122(18): 3220–9. DOI: 10.1182/blood-2013-02-482547
18. Jöris M.M., Lankester A.C., von dem Borne P.A., et al. The impact of frequent HLA haplotypes in high linkage disequilibrium on donor search and clinical outcome after unrelated haematopoietic SCT. Bone Marrow Transplantation. 2013; 48: 483–90. DOI: 10.1038/bmt.2012.189
19. BMDS. http://bmds.1spbgmu.ru
20. Picardi A., Arcese W., Pollichieni S., et al. The Rome Transplant Network model compared to the Italian Bone Marrow Donor Registry activity for unrelated donor search process and transplant efficiency for hematologic malignancy. Transfusion. 2017; 57(7): 1734–43. DOI: 10.1111/trf.14131
21. Zino E., Vago L., Di Terlizzi S., et al. Frequency and targeted detection of HLA-DPB1 T cell epitope disparities relevant in unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007; 13(9): 1031–40. DOI: 10.1016/j.bbmt.2007.05.010
22. Crocchiolo R., Zino E., Vago L., et al. Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation. Blood. 2009; 114(7): 1437–44. DOI: 10.1182/ blood-2009-01-200378
23. Fleischhauer K., Shaw B.E., Gooley T., et al. Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. Lancet Oncol. 2012; 13(4): 366–74. DOI: 10.1016/S1470- 2045(12)70004-9
24. DPB1 T-Cell Epitope Algorithm v2.0 (2016-08). https://www.ebi.ac.uk/ ipd/imgt/hla/dpb
25. Fernandez-Vina M.A., Klein J.P., Haagenson M., et al. Multiple mismatches at the low expression HLA loci DP, DQ, and DRB3/4/5 associate with adverse outcomes in hematopoietic stem cell transplantation. Blood. 2013; 121: 4603–10. DOI: 10.1182/blood-2013-02-481945
26. Passweg J.R., Schanz U., Chalandon Y., et al. High-resolution HLA matching in unrelated donor transplantation in Switzerland: differential impact of class I and class II mismatches may reflect selection of nonimmunogenic or weakly immunogenic DRB1/DQB1 disparities. Bone Marrow Transplant. 2015; 50(9): 1201–5. DOI: 10.1038/bmt.2015.129
27. Lazaryan A., Wang T., Spellman R.S., et al. Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research. Haematologica. 2016; 101: 1267–74. DOI: 10.3324/haematol.2016.143271
28. Pidala J., Lee S.J., Ahn K.W., et al. Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. Blood. 2014; 124(16): 2596–06. DOI: 10.1182/ blood-2014-05-576041
29. Fernandez-Vina M.A., Wang T., Lee S.J., et al. Identification of a permissible HLA mismatch in hematopoietic stem cell transplantation. Blood. 2014; 123(8): 1270–8. DOI: 10.1182/blood-2013-10-532671
30. Verneris M.R., Lee S.J., Ahn K.W., et al. HLA mismatch is associated with worse outcomes after unrelated donor reduced-intensity conditioning hematopoietic cell transplantation: an analysis from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015; 21(10): 1783–9. DOI: 10.1016/j.bbmt.2015.05.028
31. Kuzmich E.V., Alyanskiy A.L., Ivanova N.E., et al. Analysis of the results of allogeneic hematopoietic stem cell transplantation depending on HLA matching of the unrelated donor/recipient pair. Onkogematologiya. 2014; 9(3): 25–31 (In Russian). DOI: 10.17650/1818-8346-2014-9-3-25-31
32. Afanasiev B.V., Zubarovskaya L.S., Alyanskiy A.L., et al. Selection of donor of allogeneic hematopoietic stem cell transplantation. Rossiyskiy Jurnal detskoi gematologii i onkologii. 2016; 3(3): 30–6 (In Russian). DOI: 10.21682/2311- 1267-2016-3-3-30-36
33. Ciurea S.O., Cao K., Fernandez-Vina M., et al. The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. Bone Marrow Transplant. 2018; 53(5): 521–34. DOI: 10.1038/s41409-017-0062-8
34. Cooley S., Trachtenberg E., Bergemann T.L., et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood. 2009; 113(3): 726–32. DOI: 10.1182/blood-2008-07-171926
35. Khamaganova E.G., Parovichnikova E.N., Kuzmina L.A., et al. Effects of killer immunoglobulin-like receptor genes and their HLA-ligands on survival of patients with acute myeloid leukemias after allogeneic hematopoietic stem cell transplantation. Gematologiya i Transfuziologiya. 2017; 62(1): 29–32 (In Russian).
36. Cooley S., Weisdorf D.J., Guethlein L.A., et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010; 116(14): 2411–9. DOI: 10.1182/ blood-2010-05-283051
37. Maschan M.A. Depletion of alpha/beta-T-cells is a robust platform for haploidentical hematopoietic stem cell transplantation results improvement. Rossiyskiy Jurnal detskoi gematologii i onkologii. 2015; 2(3): 34–8 (In Russian). DOI: 10.17650/2311-1267-2015-2-3-34-38
38. Fuchs E.J. Haploidentical transplantation for hematologic malignancies: where do we stand? Hematol Am Soc Hematol Educ Program. 2012; 2012: 230–6. DOI: 10.1182/asheducation-2012.1.230
39. Ciurea S., Al Malki M.M., Fuchs E.J., et al. The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. Bone Marrow Transplant. 2019. DOI: 10.1038/s41409-019-0499-z
40. van Rood J.J., Loberiza Jr. FR., Zhang M.J., et al. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. Blood. 2002; 99: 1572–7. DOI: 10.1182/blood.V99.5.1572
41. Wang Y., Chang Y.J., Xu L.P., et al. Who is the best donor for a related HLA haplotype-mismatched transplant? Blood. 2014; 124(6): 843–50. DOI: 10.1182/blood-2014-03-563130
42. Ruggeri L., Mancusi A., Capanni M., et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood. 2007; 110: 433–40. DOI: 10.1182/blood-2006-07-038687
43. Shimoni A., Labopin M., Lorentino F., et al. Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide. Leukemia. 2019; 33(1): 230–9. DOI: 10.1038/s41375-018-0170-5
44. Eapen M., Klein J.P., Ruggeri A., et al. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood. 2014; 123(1): 133–40. DOI: 10.1182/ blood-2013-05-506253
45. van Rood J.J., Stevens C.E., Smits J., et al. Re-exposure of cord blood to noninherited maternal HLA antigens improves transplant outcome in hematological malignancies. Proc Natl Acad Sci USA. 2009; 106: 19952–7. DOI: 10.1073/ pnas.0910310106
46. Rocha V., Spellman S., Zhang M.J., et al. Effect of HLA-matching recipients to donor noninherited maternal antigens on outcomes after mismatched umbilical cord blood transplantation for hematologic malignancy. Biol Blood Marrow Transplant. 2012; 18: 1890–6. DOI: 10.1016/j.bbmt.2012.07.010
47. Cutler C., Kim H.T., Sun L., et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood. 2011; 118: 6691– 7. DOI: 10.1182/blood-2011-05-355263
Review
For citations:
Khamaganova E.G., Kuzmina L.A. ASSESSMENT OF HLA-COMPATIBILITY AND REQUIREMENTS FOR HLA-TYPING OF PATIENT AND DONOR IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. Russian journal of hematology and transfusiology. 2019;64(2):175-187. (In Russ.) https://doi.org/10.35754/0234-5730-2019-64-2-175-187
Views:
17563
Email this article 
